Classes
Publications
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Alirocumab, Praluent(R) in the light of studies2016 | First Faculty of Medicine
- Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy2012 | First Faculty of Medicine
- Therapeutic equivalence of the generic and the reference atorvastatin in patients with increased coronary risk2011 | First Faculty of Medicine
- Plasma HDL-cholesterol and triglyceride levels in familial hypercholesterolemia: Data from the MedPed CZ database and the Czech population2011 | First Faculty of Medicine
- Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia2010 | First Faculty of Medicine
- Rosuvastatine2009 | First Faculty of Medicine
- Leukocyte and endothelial adhesion molecules in patients with hypercholesterolemia: the effect of atorvastatin treatment2008 | First Faculty of Medicine
- Regional differences in physicians' behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study2023 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Jistoty a nejistoty na křižovatkách současné medicíny2023 | First Faculty of Medicine
Loading network view...